Oakstone Assessment and Treatment of Depression and Anxiety Integrating Psychopharmacology and Psychotherapy 2021

Description

+ Include: 5 videos, size: 4.61 GB

+ Target Audience: psychiatrists

+ Sample video: contact me for sample video

+ Information:

Date of Original Release: October 15, 2021
Estimated Time to Complete the Activity: 13.00 hours

PROGRAM DESCRIPTION

This seminar will familiarize the clinician with emerging strategies in the assessment and treatment of major depression, bipolar illness and anxiety disorders. The course will also highlight key comorbid conditions associated with mood and anxiety disorders, including Axis II personality disorders, management of patients with medical conditions and management of the geriatric patient. An essential theme of the seminar will be formulating an integrated psychopharmacologic and psychotherapeutic treatment approach.

Issues around the choice of specific antidepressants, mood stabilizers and anti-anxiety medications and psychopharmacologic management of the treatment resistant patient will be highlighted with a discussion of the use of augmenting medication strategies and combinations of psychopharmacologic agents. Psychotherapeutic approaches to mood and anxiety disorders will be studied with a focus on differing strategies including psychodynamic psychotherapy, cognitive and behavioral therapy, interpersonal psychotherapy for depression and other psychotherapeutic approaches. Emerging data on the role of exercise in the treatment of depressed mood and data on nutraceuticals as a supplement to antidepressant treatment will be examined.

The seminar will update the clinician on recent developments in neuropsychiatry, including brain imaging and therapeutic stimulation techniques. Recent data on the therapeutic efficacy of TMS, and different TMS modalities will be presented; emerging data on the therapeutic efficacy and risks associated with different modalities of ketamine administration will be presented as well as ketamine’s effects on suicidality. The range of anxiety disorders to be reviewed will include anxiety disorders in the Obsessive-Compulsive Disorder Spectrum including skin-picking disorder, trichotillomania and body dysmorphic disorder; anxiety disorders related to trauma including posttraumatic stress disorder. Emphasis will be placed on the integration of psychopharmacology and cognitive behavioral therapy in the treatment of anxiety disorders.

Management of anxiety in patients vulnerable to abuse of alcohol and psychological dependence on marijuana will be examined and the role of non-benzodiazepine anti-anxiety medications, such as pregabalin, will be explored in detail.

LEARNING OBJECTIVES

Upon completion of this activity, participants will be able to:
 Evaluate emerging strategies in the use of psychotropic medications in the treatment of major depression and anxiety disorders and integrate psychopharmacologic treatments into psychotherapy strategies in treating depressed and anxious patents;
 Describe strategies for the psychopharmacological and psychotherapeutic management of treatment resistant depression;
 Summarize the emerging role of ketamine in the treatment of major depression and suicidal behavior;
 Explore the role of novel enhancements to treatment of mood disorders including omega 3 fatty acids, 1 methylfolate and zinc;
 Discuss the role of electroconvulsive therapy and Transcranial Magnetic Stimulation in treatment resistant depressive disorders;
 Examine new developments in the treatment of depression in bipolar patients with a focus on newer medications including lurasidone and cariprazine;
 Identify an evidence-based approach to suicide risk assessment and prevention of suicide;
 Appreciate the role of lithium carbonate in combination with other mood stabilizing agents;
 Give examples of recent developments in psychotherapeutic approaches to treating Bipolar patients, including cognitive, behavioral and expressive psychotherapy techniques;
 Integrate psychodynamic assessment, psychotherapy and psychopharmacology into management of depression and anxiety disorders;
 Assess the role of Cognitive Behavioral Therapy (CBT) in the treatment of depression and anxiety disorders;
 Compare recent developments in the implementation of CBT, including Commitment and Acceptance Therapy and inclusion of exposure therapy in CBT;
 Report on the latest applications for computer- based treatment of OCD and other anxiety disorders;
 Describe new psychopharmacological and psychotherapeutic techniques in the treatment of PTSD including exposure and response prevention and virtual reality techniques utilized to treat PTSD secondary to exposure to combat;
 Formulate an integrated psychopharmacological and psychotherapeutic approach to personalitydisordered patients in the borderline and severely narcissistic spectrum presenting with depression and anxiety;
 Manage anxiety disorders in patients vulnerable to alcohol abuse and psychological dependence on marijuana, including the use of non-benzodiazepine anti-anxiety agents such as pregabalin and buspirone;
 Formulate strategies for treating patients with marijuana abuse disorder, including discussion of newly emerging psychopharmacological and psychotherapeutic techniques.

TARGET AUDIENCE

This educational activity was designed for health professionals in the fields of psychiatry,psychology, nursing, social work, counseling, medicine, pediatrics and surgery.

 

+ Topics:

1. Assessment _ Treatment of Major Depressive Disorder.mp4
2. Psychopharmacologic Management of Bipolar Disorder – Emerging Perspectives.mp4
3. Anxiety Disorders – Assessment _ Pharmacotherapy.mp4
4. Suicide Assessment _ Prevention, Psychotherapy of Depression _ Perspectives on Personality Disorder.mp4
5. Assessment _ Management of Depression in the Elderly _ Brain Imaging.mp4
Questions.pdf
Syllabus.pdf